De CEV, Rodríguez-Diez G

Idioma: Inglés [English version]
Referencias bibliográficas: 14
Paginas: 124-126
Archivo PDF: 252.24 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Tzeis S, Gerstenfeld E, Kalman J et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024; 26: 1-107.

2. Vinciguerra M, Dobrev D, Nattel S. Atrial fibrillation: pathophysiology, genetic and epigenetic mechanisms. Lancet. 2024; 37: 1-17.

3. Rodriguez-Diez G, Marquez-Murillo MF, Iturralde P et al. Joint Mexican Position document on the treatment of atrial fibrillation. Cardiovasc Metab Sci. 2019; 30 (3): 91-99.

4. Van Gelder I, Rienstra M, Bunting K et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45: 3314-3414.

5. Nayak S, Natarajan B, Pai RG. Etiology, pathology, and classification of atrial fibrillation. Int J Angiol. 2020; 29 (2): 65-71.

6. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271 (11): 840-844.

7. De la Chesnaye E, Revilla-Monsalve C, Rodríguez-Diez G. La asociación entre la desregulación de adipocinas y el desarrollo de la fibrilación auricular en pacientes obesos, es realmente relevante? Arch Cardiol Mex. 2024; 94 (5): 1-6.

8. Mukai Y. Inflammation and atrial fibrillation. J Arrhythm. 2024; 40 (1): 26-27.

9. He Y, Hara H, Nuñez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016; 41: 1012-1021.

10. Thihalolipavan S, Morin DP. Atrial fibrillation and congestive heart failure. Heart Fail Clin. 2014; 10 (2): 305-318.

11. Mora S, Akinkuolie AO, Sandhu RK, Conen D, Albert CM. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol. 2014; 7 (4): 612-619.

12. López Fl, Agarwal SK, Maclehose RF et al. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities' study. Circ Arrhythm Electrophysiol. 2012; 5 (1): 155-162.

13. Alonso A, yin X, Roetker NS et al. Blood lipids and the incidence of atrial fibrillation: the multi-ethnic study of atherosclerosis and the Framingham heart study. J Am Heart Assoc. 2014; 3 (5): e001211.

14. Álvarez de la Cadena J, Asensio-Lafuente E, De la Chesnaye E, Rodríguez-Diez G. Atrial fibrillation and obesity: two epidemic diseases with complex interactions. Cardiovasc Metab Sci. 2023; 34 (2): 72-75.